Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang, K.-L. | - |
dc.contributor.author | Song, M.-K. | - |
dc.contributor.author | Shin, H.-J. | - |
dc.contributor.author | Na, H.-J. | - |
dc.contributor.author | Shin, D.-H. | - |
dc.contributor.author | Kim, J.-K. | - |
dc.contributor.author | Moon, J.-H. | - |
dc.contributor.author | Ahn, J.-S. | - |
dc.contributor.author | Song, I.-C. | - |
dc.contributor.author | Hong, J. | - |
dc.contributor.author | Lee, G.-W. | - |
dc.contributor.author | Chung, J.-S. | - |
dc.date.available | 2020-02-28T18:44:29Z | - |
dc.date.created | 2020-02-12 | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 2287-979X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12974 | - |
dc.description.abstract | Background Azacitidine (AZA) is standard care for patients with myelodysplastic syndrome (MDS) who have not had allogeneic stem cell transplantation. Chromosomal abnormalities (CA)including complex karyotype (CK) or monosomal karyotype (MK) are associated with clinical outcome in patients with MDS. Methods We investigated which prognostic factors including CAs would predict clinical outcomes in patients with International Prognostic Scoring System (IPSS) higher risk MDS treatedwith AZA, retrospectively. CK was defined as the presence of three or more numerical or structural CAs. MK was defined as the presence of two or more distinct autosomal monosomies or single autosomal monosomy with at least one additional structural CA. Results A total of 243 patients who treated with AZA, were enrolled. CK was present in 124 patientsand MK was present in 90 patients. Bone marrow blasts ≥15% and CK were associated with poorer response (P=0.038, P=0.007) and overall survival (OS) (P>0.001, P >0.001) independently. Although MK in CK group was not associated with prognosis, non-MK status in non-CK group reflected favorable OS (P=0.005). The group including <3 CAs was associated with poorer OS (group including >3 CAs vs. only three CAs, P=0.001; group with <3 CAs vs. only three CAs, P=0.001). Conclusion CK was an important prognostic parameter associated with worse outcome. MK may predict poor survival in only non-CK status. The higher number of CAs was associated with poorer survival. © 2014 Korean Society of Hematology. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Korean Society of Hematology | - |
dc.relation.isPartOf | Blood Research | - |
dc.subject | azacitidine | - |
dc.subject | hydroxyurea | - |
dc.subject | adult | - |
dc.subject | aged | - |
dc.subject | Article | - |
dc.subject | cancer chemotherapy | - |
dc.subject | cancer prognosis | - |
dc.subject | cancer survival | - |
dc.subject | cancer survivor | - |
dc.subject | chromosome 5 | - |
dc.subject | chromosome 7 | - |
dc.subject | chromosome aberration | - |
dc.subject | complex karyotype | - |
dc.subject | controlled study | - |
dc.subject | cytogenetics | - |
dc.subject | drug dose reduction | - |
dc.subject | female | - |
dc.subject | follow up | - |
dc.subject | human | - |
dc.subject | International Prognostic Scoring System | - |
dc.subject | karyotype | - |
dc.subject | major clinical study | - |
dc.subject | male | - |
dc.subject | monosomal karyotype | - |
dc.subject | myelodysplastic syndrome | - |
dc.subject | myeloproliferative neoplasm | - |
dc.subject | outcome assessment | - |
dc.subject | overall survival | - |
dc.subject | retrospective study | - |
dc.subject | sex ratio | - |
dc.subject | therapy delay | - |
dc.subject | treatment duration | - |
dc.title | Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.doi | 10.5045/br.2014.49.4.234 | - |
dc.identifier.bibliographicCitation | Blood Research, v.49, no.4, pp.234 - 240 | - |
dc.identifier.kciid | ART001937018 | - |
dc.identifier.scopusid | 2-s2.0-84920995801 | - |
dc.citation.endPage | 240 | - |
dc.citation.startPage | 234 | - |
dc.citation.title | Blood Research | - |
dc.citation.volume | 49 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Hong, J. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Azacitidine | - |
dc.subject.keywordAuthor | Chromosomal abnormalities | - |
dc.subject.keywordAuthor | Complex karyotype | - |
dc.subject.keywordAuthor | Monosomal karyotype | - |
dc.subject.keywordAuthor | Myelodysplastic syndrome | - |
dc.subject.keywordPlus | azacitidine | - |
dc.subject.keywordPlus | hydroxyurea | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | cancer chemotherapy | - |
dc.subject.keywordPlus | cancer prognosis | - |
dc.subject.keywordPlus | cancer survival | - |
dc.subject.keywordPlus | cancer survivor | - |
dc.subject.keywordPlus | chromosome 5 | - |
dc.subject.keywordPlus | chromosome 7 | - |
dc.subject.keywordPlus | chromosome aberration | - |
dc.subject.keywordPlus | complex karyotype | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | cytogenetics | - |
dc.subject.keywordPlus | drug dose reduction | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | International Prognostic Scoring System | - |
dc.subject.keywordPlus | karyotype | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | monosomal karyotype | - |
dc.subject.keywordPlus | myelodysplastic syndrome | - |
dc.subject.keywordPlus | myeloproliferative neoplasm | - |
dc.subject.keywordPlus | outcome assessment | - |
dc.subject.keywordPlus | overall survival | - |
dc.subject.keywordPlus | retrospective study | - |
dc.subject.keywordPlus | sex ratio | - |
dc.subject.keywordPlus | therapy delay | - |
dc.subject.keywordPlus | treatment duration | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.